Gastroesophageal (GE) Junction Carcinomas Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Gastroesophageal (GE) Junction Carcinomas – Pipeline Review, H1 2015” to its store. The report provides an overview of the Gastroesophageal (GE) Junction Carcinomas’s therapeutic pipeline.

Gastroesophageal (GE) Junction Carcinomas Therapeutic Pipeline Review 2015

Gastroesophageal (GE) Junction Carcinomas Therapeutic Pipeline Review 2015

Past News Releases

RSS

The report “Gastroesophageal (GE) Junction Carcinomas – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Gastroesophageal (GE) Junction Carcinomas. The gastroesophageal junction lies at the top of the stomach in the upper abdomen. Conditions that afflict the gastroesophageal junction include hiatal hernia. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/gastroesophageal-ge-junction-carcinomas-pipeline-review-h1-2015-market-report.html .

The report also reviews key players involved in the therapeutic development for Gastroesophageal (GE) Junction Carcinomas and special features on late-stage and discontinued projects. Companies discussed in this Gastroesophageal (GE) Junction Carcinomas – Pipeline Review, H1 2015 report include Amgen Inc., Aslan Pharmaceuticals Pte. Ltd., AstraZeneca PLC, Basilea Pharmaceutica AG, Bristol-Myers Squibb Company, Celltrion, Inc., Exelixis, Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Merck & Co., Inc., Merck KGaA, Merrimack Pharmaceuticals, Inc., Ono Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are avelumab, BAL-101553, cabozantinib s-malate, DKN-01, gefitinib, GS-5745, ipilimumab, MK-2206, MM-111, nimotuzumab, nivolumab, pertuzumab, SNX-5422, trastuzumab biosimilar, trebananib and varlitinib. Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314345 . (This is a premium report priced at US$2000 for a single user License.)

List of Tables

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9
Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Amgen Inc., H1 2015 16
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 17
Gastroesophageal (GE) Junction Carcinomas - Pipeline by AstraZeneca PLC, H1 2015 18
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Basilea Pharmaceutica AG, H1 2015 19
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Bristol-Myers Squibb Company, H1 2015 20
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Celltrion, Inc., H1 2015 21
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Exelixis, Inc., H1 2015 22
Gastroesophageal (GE) Junction Carcinomas - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Gilead Sciences, Inc., H1 2015 24
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck & Co., Inc., H1 2015 25
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merck KGaA, H1 2015 26
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 27
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 28
Gastroesophageal (GE) Junction Carcinomas - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Assessment by Combination Products, H1 2015 31
Number of Products by Stage and Target, H1 2015 33
Number of Products by Stage and Mechanism of Action, H1 2015 35
Number of Products by Stage and Route of Administration, H1 2015 37
Number of Products by Stage and Molecule Type, H1 2015 39
Gastroesophageal (GE) Junction Carcinomas Therapeutics - Recent Pipeline Updates, H1 2015 82
Gastroesophageal (GE) Junction Carcinomas - Dormant Projects, H1 2015 115
Gastroesophageal (GE) Junction Carcinomas - Discontinued Products, H1 2015 116

List of Figures

Number of Products under Development for Gastroesophageal (GE) Junction Carcinomas, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 14
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Top 10 Targets, H1 2015 32
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 36
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36
Number of Products by Top 10 Molecule Types, H1 2015 38
Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Explore more reports on Cancer Drugs industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/cancer-drugs .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website